CNSA 26th Annual Congress |19 - 21 June 2024 | Brisbane Convention and Exhibition Centre | innovation quality care in a digital era

About the Breakfast Sessions

Breakfast sessions are available for all delegates to attend (excluding exhibitors) and spaces are limited and strictly on a first come first serve basis. A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence. 

Please click on the links below for more information on the breakfast topics. In order to attend the breakfast sessions, you will be required to indicate your attendance as part of your registration form.

Wednesday 19 June

Breakfast session supported by Gilead

Breakfast session supported by Slater and Gordon Lawyers

Thursday 20 June

Breakfast Session 1 - Supported by Lilly

Breakfast Session 2 - Supported by AstraZeneca

Friday 21 June

Breakfast Session 1 - Supported by Merck

Breakfast Session 2 - Supported by Astellas 

Wednesday 19 June

Breakfast Session 1

Title: TBC

Time: 0800 - 0900 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.30am - 8.00am). This will be served outside the meeting room.

Presenters: TBC

Description: TBC


Breakfast Session 2

Title: Dust and Occupational Cancers

Time: 0830 - 0930 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (8.00am - 8.30am). This will be served outside the meeting room.

Presenters: 

Sean Sweeney – Senior Associate, Asbestos and Dust Diseases

Raelene Lingam – Legal Counsel, Asbestos and Dust Diseases

Tracy Madden – Senior Legal Counsel, Asbestos and Dust Diseases

Description: 

Overviews of occupational cancers including:

  • Mesothelioma and asbestos-related cancer 
  • Silicosis and silica-related lung cancer 
  • Other cancers, including bladder cancer, melanoma, Leukemia, pancreatic cancer, nasal cancer, non-Hodgkin’s lymphoma 
 

Types of carcinogens and ‘at-risk’ industries, including firefighters, painters, welders, those exposed to engine exhaust, mould or pesticides

Entitlements to common law and statutory compensation and the general process of a claim

Terminal illness and total and permanent disability entitlements

Case studies

Future predictions based on current research  

Q&A

 

Thursday 20 June

Breakfast Session 1

Title: VERZENIO in high-risk* HR+, HER2- early breast cancer: Explaining the role of Verzenio to Patients

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenters: Associate Professor Liz Caldon and Cath Griffiths

Description: 

Join us for an educational symposium where Associate Prof Liz Caldon, Garvan Institute of Medical Research will explore the mode of action for Verzenio and the role it plays in combination with ET in high-risk HR+, HER2- EBC patients. Cath Griffiths, Early Breast Cancer Nurse at Breast Cancer Research centre, Perth will share her experience in successfully introducing, monitoring, and managing such patients whilst on Verzenio + ET for adjuvant treatment. 

EBC: early breast cancer, ET: Endocrine Therapy HER2-: human epidermal growth factor receptor 2 negative, HR+: hormone receptor positive

*High-risk EBC was defined as patients who had 4 or more positive nodes, or 1–3 positive nodes with either grade 3 disease, tumour size ≥5 cm, or a Ki-67 index ≥20%.1–3

References: 1. VERZENIO Approved Product Information. 2. Johnston SR et al. J Clin Oncol. 2020;38(34):3987–98. 3. Fasching P et al. Breast Cancer Res Treat.

2019;175(3):617–25. PP-AL-AU-0723 Apr 2024


 

Breakfast Session 2

Title: Empowering Nursing Excellence: Innovative Models of Care and Business Strategies for Tomorrow's Healthcare

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenters: TBC

Description: TBC


Friday 21 June

Breakfast Session 1

Title: ONCADERM Education: Identify and manage cutaneous reactions in patients being treated with EGFR inhibitors.

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenter: Professor Pablo Fernández-Peñas

Description: 

The ONCADERM program aims to provide structured education to assist with the prevention, early identification and optimal management of cutaneous reactions associated with EGFR inhibitor therapy. 

Learning Outcomes: 

  • Understand the mechanism of action of how the EGFR inhibitor affects the structure and function of the skin
  • Recognise and describe the various cutaneous reactions that occur in patients being treated with EGFR inhibitors
  • Follow general management pathways for treating cutaneous reactions associated with EGFR inhibitor treatment
 
Please click here for more information about this session. 
 

Breakfast Session 2

Title: Changing management of GU cancers: A practical guide

Time: 0730 - 0830 - A stand-up buffet breakfast will be provided and available 30 minutes before the sessions commence (7.00am - 7.30am). This will be served outside the meeting room.

Presenter: Marc Diocera, Nurse Consultant, Peter MacCallum Cancer Centre

Description: TBC